POEM-F for Achalasia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment approach for achalasia, a condition that makes swallowing difficult due to esophageal issues. It compares the standard procedure, POEM (Peroral Endoscopic Myotomy), with a new method, POEM-F (Per-oral Endoscopic Myotomy with Fundoplication), which includes an additional step to reduce heartburn after treatment. The goal is to determine if POEM-F can lower the risk of post-treatment heartburn (GERD) compared to the standard method. Adults with type I or II achalasia who haven't undergone major esophageal surgery may qualify for this trial. As an unphased trial, this study provides patients the chance to contribute to innovative research that could enhance future treatment options.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this technique is safe for achalasia patients?
Studies have shown that the standard POEM procedure is safe and effective for treating achalasia, a condition that makes swallowing difficult. Research indicates that this procedure has a low rate of side effects and is well-tolerated by most patients. Reports show good long-term results, with many patients experiencing relief from symptoms.
For POEM-F, which includes an extra step to help prevent acid reflux (GERD) after the procedure, early findings suggest it is also safe and practical. A meta-analysis found that POEM-F is a good option for patients with achalasia. It seems to address the main downside of the standard POEM, which is the risk of acid reflux, without adding significant safety concerns.
Both treatments have demonstrated promising safety records in studies. Prospective trial participants should know that experts are carefully evaluating these treatments to ensure maximum safety.12345Why are researchers excited about this trial?
Researchers are excited about the new technique, POEM-F, for achalasia because it adds a fundoplication step to the conventional per-oral endoscopic myotomy (POEM). This extra step potentially reduces post-procedure gastroesophageal reflux, a common complication with traditional POEM. By combining myotomy with fundoplication, the procedure aims to improve patient outcomes by enhancing the durability of the treatment and minimizing reflux-related side effects. This innovative approach could offer a more comprehensive solution for achalasia patients who currently rely on treatments like medication, pneumatic dilation, or surgery.
What evidence suggests that POEM-F could be an effective treatment for achalasia?
This trial will compare two treatments for achalasia: Conventional POEM and POEM-F. Research has shown that both POEM and POEM-F effectively treat achalasia, a condition affecting the esophagus. Participants may receive Conventional POEM, which improves esophageal function with a high success rate of about 86-89% after one year. However, it can cause acid reflux, or GERD, in up to 50-60% of patients. Alternatively, participants may receive POEM-F, which early studies suggest can relieve achalasia symptoms while reducing the chance of GERD to about 12% after one year. Both treatments are safe and effective, but POEM-F appears to lower the risk of GERD compared to traditional POEM.36789
Who Is on the Research Team?
Hon Chi Yip, FRCSEd
Principal Investigator
Chinese University of Hong Kong
Are You a Good Fit for This Trial?
Adults aged 18-65 with symptomatic achalasia types I or II, who are either treatment-naive or have had unsuccessful balloon dilation. Excluded are those with prior esophageal surgery, significant comorbidities preventing anesthesia, obesity (BMI ≥ 30), pregnancy, breastfeeding, large hiatal hernias, or certain blood conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either POEM-F or conventional POEM procedure
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of GERD and other outcomes
Long-term Follow-up
Extended monitoring of GERD and other outcomes beyond the primary follow-up period
What Are the Treatments Tested in This Trial?
Interventions
- Conventional POEM
- POEM-F
Conventional POEM is already approved in European Union, United States, India, China for the following indications:
- Esophageal achalasia
- Esophageal achalasia
- Esophageal achalasia
- Esophageal achalasia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Chinese University of Hong Kong
Lead Sponsor
Deenanath Mangeshkar Hospital and Research Centre
Collaborator
Johns Hopkins University
Collaborator
Northwestern University Feinberg School of Medicine
Collaborator
Asian Institute of Gastroenterology, India
Collaborator
Post Graduate Institute of Medical Education and Research, Chandigarh
Collaborator
Nanfang Hospital, Southern Medical University
Collaborator
Post Graduate Institute of Medical Education and Research, Chandigarh
Collaborator